Kiora Pharmaceuticals (KPRX) Revenue (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly Revenue came in at $16.0 million in Q1 2024, up 132580.99% on a QoQ basis from $12059.0 in Q4 2020.

Kiora Pharmaceuticals (KPRX) Revenue (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has 6 years of Revenue data on file, last reported at $16.0 million in Q1 2024.

Quarterly Revenue changed N/A year-over-year to $16.0 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $16.0 million (changed N/A YoY) and the FY2024 annual result came in at $16.0 million, changed N/A from the prior year.
Revenue rose to $16.0 million in Q1 2024, from $12059.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $16.0 million in Q1 2024 to a low of $12059.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.59 Bn	131.73 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.21 Bn	78.22 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	65.65 Bn	60.47 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	674.14 Mn
10	Kiora Pharmaceuticals	16.06 Mn	16.06 Mn	-	-

Download Data